More back and forth as Abbvie talks up benefits of Shire acquisiton
By Nuala Moran
Wednesday, June 25, 2014
LONDON Is it the tax break or the products? Abbvie Inc. launched its public campaign to acquire Shire plc for $47 billion, promising synergies in the pipelines and the opportunity to use its marketing heft to expand Shire's rare diseases and attention deficit hyperactivity disorder (ADHD) franchises.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.